What is HC Wainwright’s Estimate for SLDB FY2026 Earnings?

Solid Biosciences Inc. (NASDAQ:SLDB) – Analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Solid Biosciences in a report issued on Thursday, November 5th. HC Wainwright analyst A. He now anticipates that the company will post earnings of ($1.60) per share for the year, up from their previous forecast of ($1.63). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q4 2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.39) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.39) EPS and FY2027 earnings at ($1.56) EPS.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.05.

A number of other equities research analysts have also recently commented on the company. Loop Capital set a $25.00 target price on Solid Biosciences in a research report on Monday, September 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Solid Biosciences in a report on Thursday, October 15th. Royal Bank Of Canada began coverage on Solid Biosciences in a report on Wednesday, September 16th. They issued an “outperform” rating and a $18.00 price target for the company. Truist Financial increased their price target on Solid Biosciences from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, August 21st. Finally, Cantor Fitzgerald raised their price objective on Solid Biosciences from $16.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Solid Biosciences Trading Up 2.1%

Shares of Solid Biosciences stock opened at $7.17 on Monday. The firm has a 50-day simple moving average of $7.38 and a two-hundred day simple moving average of $7.67. Solid Biosciences has a fifty-two week low of $4.05 and a fifty-two week high of $11.45.

Hedge Funds Weigh In On Solid Biosciences

A number of large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC lifted its holdings in Solid Biosciences by 0.6% during the first quarter. Perceptive Advisors LLC now owns 11,906,646 shares of the company’s stock valued at $85,728,000 after purchasing an additional 73,107 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Solid Biosciences in the first quarter valued at about $28,877,000. Redmile Group LLC increased its stake in shares of Solid Biosciences by 8.1% during the first quarter. Redmile Group LLC now owns 2,011,895 shares of the company’s stock worth $14,486,000 after purchasing an additional 151,353 shares in the last quarter. Monashee Investment Management LLC increased its stake in shares of Solid Biosciences by 5.2% during the first quarter. Monashee Investment Management LLC now owns 1,420,295 shares of the company’s stock worth $10,226,000 after purchasing an additional 70,524 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Solid Biosciences by 40.8% during the first quarter. Dimensional Fund Advisors LP now owns 956,135 shares of the company’s stock worth $6,877,000 after purchasing an additional 277,051 shares in the last quarter. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

Solid Biosciences is a biotechnology company developing genetic medicines for Duchenne muscular dystrophy and other serious neuromuscular and cardiac diseases. The company’s research focuses on gene-transfer approaches intended to address underlying causes of these conditions. Its lead program, SGT-003, is an investigational gene therapy being developed for Duchenne muscular dystrophy. Solid Biosciences also has research programs targeting other rare diseases. These programs are in development, and its therapies have not been established as approved treatments.